Volume 27, Number 1—January 2021
Research
Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France
Floriane Gallais, Aurélie Velay, Charlotte Nazon, Marie-Josée Wendling, Marialuisa Partisani, Jean Sibilia, Sophie Candon, and Samira Fafi-Kremer
Table 2
Humoral and cellular immune response to SARS-CoV-2 of COVID-19 patients and their contacts 44–102 days after symptom onset, Strasbourg, France, 2020*
| ID† |
Lymphocyte count, × 109/L |
Days from symptom onset to sample collection |
SARS-CoV-2 serologic test result |
Assay results |
SARS-CoV-2–specific T-cell response (no. antigens) |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| Biosynex Antigen: RBD of protein S |
Abbott Architect Antigen: protein N (index value) | Euroimmun Antigen: protein S (index value) | ||||||||
| IgM |
IgG |
IgG |
IgG/IgA |
|||||||
| Couples with symptomatic contacts |
||||||||||
| P1 | 1.3 | 58 | Pos | Neg | Pos | Pos (3.36) | Pos (2.28)/neg | Pos (5)† | ||
| C1 |
1.8 |
53 |
Neg |
Neg |
Neg |
Neg |
Neg/neg |
Pos (4)† |
||
| P2 | 2.0 | 51 | Pos | Neg | Pos | Pos (4.3) | Pos (2.3)/neg | Pos (7)† | ||
| C2 |
1.5 |
44 |
Neg |
Neg |
Neg |
Neg |
Neg/neg |
Neg (1) |
||
| P4 | 1.6 | 57 | Pos | Pos | Pos | Pos (6.48) | Pos (4.24)/pos (4.16) | Pos (4)† | ||
| C4 |
1.7 |
51 |
Neg |
Neg |
Neg |
Neg |
Neg/neg |
Pos (3)† |
||
| P5 | 1.6 | 68 | Pos | Pos | Pos | Pos (3.97) | Pos (4.86)/pos (2.38) | Pos (7)† | ||
| C5 |
2.0 |
80 |
Neg |
Neg |
Neg |
Neg |
Neg/neg |
Pos (3)† |
||
| P7 | 1.3 | 64 | Pos | Pos | Neg | Pos (4.18) | Pos (3.43)/doubtful (0.94) | Pos (4)† | ||
| C7 |
2.2 |
64 |
Neg |
Neg |
Neg |
Neg |
Neg/neg |
Neg (1) |
||
| P8 | 1.9 | 102 | Pos | Pos | Pos | Pos (7.55) | Pos (5.39)/pos (9.23) | Pos (5)† | ||
| C8 |
1.9 |
93 |
Neg |
Neg |
Neg |
Neg |
Neg/neg |
Pos (4)† |
||
| Couples with asymptomatic contacts |
||||||||||
| P3 | 1.7 | 49 | Pos | Pos | Pos | Pos (8.4) | Pos (7.23)/pos (3.83) | Pos (8)† | ||
| C3 |
1.5 |
NA |
Neg |
Neg |
Neg |
Neg |
Neg/Neg |
Neg (0) |
||
| P6 | 2.1 | 69 | Pos | Pos | Pos | Pos (6.37) | Pos (5.73)/pos (2.49) | Pos (6)† | ||
| C6 |
2.2 |
NA |
Neg |
Neg |
Neg |
Neg |
Neg/doubtful (0.85) |
Neg (1) |
||
| P9 | 2.4 | 88 | Pos | Pos | Pos | Pos (7.48) | Pos (7.02)/pos (5.98) | Pos (6)† | ||
| C9 |
3.0 |
NA |
Neg |
Neg |
Neg |
Neg |
Neg/neg |
Neg (1) |
||
| P10 | 1.9 | 99 | Pos | Pos | Neg | Pos (2.46) | Pos (1.75)/doubtful (0.95) | Pos (5)† | ||
| C10 |
1.1 |
NA |
Neg |
Neg |
Neg |
Neg |
Neg/neg |
Neg (1) |
||
| P11 | 1.7 | 100 | Pos | Neg | Pos | Neg | Pos (4.01)/pos (1.72) | Pos (6)† | ||
| C11 | 1.9 | NA | Neg | Neg | Neg | Neg | Neg/neg | Neg (0) | ||
*In ID column, same number indicates P and C are partners in 1 couple. C, contact; ID, identification; neg, negative; P, index patient; pos, positive; PBMC, peripheral blood mononuclear cells; NA, not applicable; RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Page created: September 29, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.